Contact

Steady Lantern 35 Home About Services Policy Tracker Safety & Evidence Access Guide Contact Independent resource · September 2026 Ibogaine News: Research, Policy And Safety Updates A careful guide to emerging ibogaine research, changing policy, and the safety questions that matter before preliminary findings are mistaken for established care. Working principle: promising research is not the same as established treatment. Evidence before hype · Risk clarity 01 / Research Signals, not certainty Ibogaine research breakthroughs Ibogaine is a psychoactive substance derived primarily from the root bark of Tabernanthe iboga , a plant with long-standing ceremonial importance in Bwiti traditions. Current research asks whether its unusual pharmacology could have therapeutic potential for drug addiction, especially opioid dependence, alcohol use, and stimulant use. Its history and chemistry are outlined in the reference overview of ibogaine , but clinical meaning still depends on stronger evidence. Recent preclinical research studies have explored substance use disorder beyond opioids, including alcohol and stimulants. Researchers are also examining noribogaine, an active metabolite that may help explain long-lasting neurological effects through modulation of neuroplasticity and other neurobiological mechanisms. A live scholarly search on the topic is useful for seeing how quickly this research base is changing. That interest has broadened the conversation about addiction treatment, but it has not removed uncertainty. Small studies, changing protocols, and difficult patient selection mean that anecdotal evidence cannot settle questions about long-term effects, comparative benefit, or who faces unacceptable risk. Proof line / The therapeutic signal is unusually interesting; the cardiac risk is unusually serious. Some clinical trials are investigating lower-dose ibogaine and synthetic ibogaine analogs intended to retain possible therapeutic benefits while reducing adverse ef

Contact

Published channels